NORCROSS, Ga., Dec. 13 /PRNewswire-FirstCall/ -- Immucor, Inc. , the global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that its Board of Directors has authorized the Company to repurchase up to an additional 1,000,000 shares of its common stock. The Company announced on November 11, 2005 that the Company’s Board of Directors had authorized the Company to resume purchases under its existing stock repurchase plan. As of November 11, 2005 1,002,750 shares were authorized for repurchase under the plan.
“We have seen our cash balance grow significantly, weighed our alternatives and believe the best way to enhance shareholder value is by re-purchasing stock. The combined programs give us the opportunity to repurchase an additional 1,260,150 shares. Since reinstituting the stock repurchase plan in November we have repurchased 742,600 shares,” said Dr. Gioacchino De Chirico, President of Immucor. Dr. De Chirico also noted that the Company is not committed to purchase any minimum number of shares, and the Company may terminate the repurchase program at any time.
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at www.immucor.com.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor’s expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as “plans,” “expects,” “believes,” “anticipates,” “estimates,” “projects,” “will,” “should” and other words of similar meaning. Further risks are detailed in Immucor’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements.
Immucor, Inc.
CONTACT: Edward Gallup of Immucor, Inc., +1-770-441-2051
Web site: http://www.immucor.com/